Resources

Epitopea announced the appointment of Lisa Butterfield to its Scientific Advisory Board (SAB).

Aravax has added Carsten Hellmann and Andrew Oxtoby to its board.

‍Nemera and Therakind have partnered on DriDose® dry powder intranasal technology.

Fermtech has raised £2.5m to scale Koji Cocoa™, a fermentation-based cocoa ingredient made from cocoa shells that delivers 25–33% cost savings and up to 98% lower carbon emissions.

Scottish bio-based chemical manufacturer Celtic Renewables is collaborating on a three-month project with Aberdeen-based microbiology company NCIMB.

British Growth Partnership Fund I achieves a first close of £200 million, with commitments from Aegon UK, Cushon Master Trust, M&G, and the British Business Bank.

Semarion has raised $3.8 million USD (£2.9 million GBP)

We’re delighted to announce that the Milner Therapeutics Institute will play an active role at BioTrinity 2026!

Significant milestone for Poolbeg's global intellectual property portfolio

Senior figures from across industry, academia, investment and government met at the House of Lords, for a roundtable hosted by The Lord Ranger of Northwood to discuss the findings of a new report.

PIR International was delighted to partner with Anaveon on the appointment of Thaminda Ramanayake as Chief Executive Officer.

Biorecycling startup Epoch Biodesign announced that it has raised $12 million in a new funding round.

Mestag Therapeutics announced the closing of a $40 million financing

ARC West London and Imperial College London’s Imperial Incubator have announced the two winning startups of the Leap Lab Pass.

Complement Therapeutics (CTx, has dosed the first patient in Opti-GAIN.

RxCelerate launched RxPlorer™: a new technology for finding small molecule hits, particularly against challenging, previously undruggable targets.

Abselion has appointed Dale Gordon as Chair of the Board of Directors.

Salvivo has been awarded £99,080 in Innovate UK Analysis for Innovators funding to enable evaluation of its FishburneTabs™ platform for biomarker detection with the National Physical Laboratory (NPL).

New parliamentary scrutiny of the UK’s innovation landscape has reinforced longstanding concerns about how investment in innovation is distributed across the country, with Pioneer Group, a specialist in technology infrastructure and venture building, urging swift action to address persistent barriers to research commercialisation.

Sonjoy Brahma, tranScrip’s VP of Clinical Operations, joins Joab Williamson of Faron Pharmaceuticals to unpack the operational realities of life in a small emerging biotech. They’ll explore the pressures of rare oncology development, how cash runway and clinical milestones shape decision-making and why flexibility, external expertise and careful planning are essential to moving programmes forward with confidence.